The Obesity Epidemic: The Lack of Access to Care and Treatment

March 4, 2021 12:00 PM - 1:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 3/4/2021 12:00:00 PM 3/4/2021 1:00:00 PM The Obesity Epidemic: The Lack of Access to Care and Treatment

Obesity is defined as a disease. Today obesity is one of the major cost drivers to our health care system, linked to diabetes, cardiovascular disease, and cancer. There is ever-increasing medical evidence to support broader access to both evidence-based prevention programs in the community and active medical treatment of obesity. But proper care and treatment of obesity faces challenges in the form of perception, stigma, bias, and roadblocks to accessing treatment, therapies, and care that can help patients. This forum, sponsored by Novo Nordisk, will address these issues and more. 

Webinar, click "live-stream" button to view

Obesity is defined as a disease. Today obesity is one of the major cost drivers to our health care system, linked to diabetes, cardiovascular disease, and cancer. There is ever-increasing medical evidence to support broader access to both evidence-based prevention programs in the community and active medical treatment of obesity. But proper care and treatment of obesity faces challenges in the form of perception, stigma, bias, and roadblocks to accessing treatment, therapies, and care that can help patients. This forum, sponsored by Novo Nordisk, will address these issues and more. 

Corporate Vice President, Head of Global R&D Business Development, Novo Nordisk
John McDonald joined Novo Nordisk in October 2018. Prior to Novo John held various roles at Biogen Inc., MPM Capital, Genzyme Corporation, Millennium Pharmaceuticals, and Genentech. In his career, John has led or participated in the evaluating, structuring and negotiating of numerous mergers and acquisitions, licenses and strategic alliances, including Biogen’s collaborations with Sangamo BioSciences, AGTC, Mitsubishi Tanabe, UCB, and Portola Pharmaceuticals, Inc. and Biogen’s acquisition of Stromedix, Inc., Millennium's Ex-U.S. collaboration with Ortho Biotech/Johnson & Johnson for VELCADE, the restructuring of Millennium's relationship with Schering-Plough Corp. for INTEGRILIN, and the sale of Millennium's interest in its CAMPATH joint venture, Genzyme’s alliance with BioMarin for ALDURAZYME, and Genentech’s alliances with Xoma Corporation (RAPTIVA), and IDEC Pharmaceuticals (RITUXAN). John holds a J.D. from the University of California, Hastings College of Law, and an M.B.A., Beta Gamma Sigma, and a B.S., Phi Beta Kappa, from the Haas School of Business, University of California, Berkeley.

Brought to you by